Next Generation Antibiotics


Multiresistant-bacteria represent an unmet medical need
Currently applied antibiotics suffer from a narrow scope of protein targets leading to fast acquisition of diverse and intricate resistance strategies. Additionally, treatment is impaired by bacterial populations that either switch into a dormant persister state or form surface attached biofilm communities. Modification of existing compound classes is not a long term solution underlining the urgent need for structurally novel, resistance-free antibacterial compounds with a new mode of action.

Small molecules addressing unprecedented bacterial protein targets
In-house screening followed by chemical modification of a hit molecule led to the identification of a potent antibiotic with an unprecedented mode of action: aBA024 shows a MIC of 300 nM against various strains including MRSA, exceeding the potency of last-resort antibiotics such as vancomycin and linezolid. Moreover, it eradicates persisters and eliminates biofilms. Resistance development could not be detected. A proof-of-concept study in a mouse infection model already revealed suitable pharmacological properties including oral bioavailability and efficacy.


Team aBACTER

Dr. Franziska Mandl
Scientist, Chemistry
Dr. Christian Fetzer
Scientist, Chemistry
Dr. Mathias Hackl
Scientist, Biochemistry
Prof. Dr. Stephan A. Sieber
Professor and Chair of Organic Chemistry, Project Leader